Envoy Medical(COCH.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Envoy Medical
COCH.US
Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc.
1.353 T
COCH.USMarket value -Rank by Market Cap -/-

Financial Score

28/01/2026 Update
D
Health Care EquipmentIndustry
Industry Ranking134/176
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE219.58%A
    • Profit Margin-10475.00%E
    • Gross Margin-383.33%E
  • Growth ScoreD
    • Revenue YoY-25.18%E
    • Net Profit YoY-7.84%C
    • Total Assets YoY-12.94%E
    • Net Assets YoY59.36%A
  • Cash ScoreD
    • Cash Flow Margin-0.73%D
    • OCF YoY-25.18%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreE
    • Gearing Ratio192.05%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Envoy Medical Signs Warrant Amendment With Meteora Parties

    Envoy Medical has amended its Shortfall Warrants with the Meteora Parties, extending the expiration date to December 31, 2026. The 1,125,499 warrants will have an exercise price determined by a weekly VWAP formula, with a minimum price of $1.50 per share. The shares from the exercise and resale of the warrants are registered under the company's effective Form S-3. This amendment aims to enhance financing flexibility.

    TradingView·
    US
    COCH
    -1.44%
    TradingView·
    US
    COCH
    -1.44%

    Envoy Medical Hits Enrollment Milestone in Pivotal Acclaim Cochlear Implant Trial

    Envoy Medical Inc. has reached the midway point in enrollment for its pivotal Acclaim® cochlear implant trial, aiming for completion by early 2026. The implant uses a piezoelectric sensor to capture sound naturally. Results are pending post-enrollment. This AI-generated brief is informational, not financial advice.

    Reuters·
    US
    COCH
    -1.44%
    Reuters·
    US
    COCH
    -1.44%

    Envoy Medical Updates Investors on Strategic Plans

    Envoy Medical has updated investors on its strategic plans, focusing on the development of its Acclaim CI, a fully-implanted cochlear implant. The company aims to complete pivotal trial enrollment by Q1 2026 and seeks FDA approval by the end of 2027. With 2.8 million potential candidates in the U.S., Envoy Medical targets a significant share of the cochlear implant market. Despite positive corporate events, the company faces financial challenges and the risk of Nasdaq delisting.

    Tip Ranks·
    US
    COCH
    -1.44%
    Tip Ranks·
    US
    COCH
    -1.44%

    Envoy Medical Secures Australian Patent for Fully Implanted Cochlear Implant Innovation

    Envoy Medical Inc. has been granted Australian Patent No. 2022229818 for its fully implanted cochlear implant technology, aimed at improving the input signal-to-noise ratio. This patent, issued on October 16, 2025, strengthens the company's global intellectual property portfolio and competitive position in the hearing health industry.

    Reuters·
    US
    COCH
    -1.44%
    Reuters·
    US
    COCH
    -1.44%

    Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant | COCH Stock News

    Envoy Medical has completed the first set of activations in the final stage of its pivotal clinical study for the Acclaim cochlear implant. The study is progressing well, with no serious adverse events reported. The Acclaim implant is fully implanted, using the ear's natural anatomy to capture sound, and does not require external components. Full enrollment is expected in early 2026, and the company anticipates strong commercial demand.

    StockTitan·
    US
    COCH
    -1.44%
    StockTitan·
    US
    COCH
    -1.44%
    © 2026 Longbridge｜Disclaimer